TG Therapeutics, Inc.(TGTX) Stock Research - Grey Stern Research

TG Therapeutics, Inc. (TGTX) Stock Analysis

$40.20 (-1.45%)

TGTX Financial Performance


Use the table below to view TG Therapeutics, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q4 - 2024

Metric Value Ranking among Peers
Price $40.20 -
52 Week Low $12.93 -
52 Week High $43.32 -
Market Cap $6.3 Billion 4/11
Gross Margin 86% 6/11
Profit Margin 22% 4/11
EBITDA margin 30% 1/11
Q4 - 2024 Revenue $108.2 Million 2/11
Q4 - 2024 Earnings $23.3 Million 4/11
Q4 - 2024 Free Cash Flow -$25.7 Million 6/11
Trailing 4 Quarters Revenue $329.0 Million 2/11
Trailing 4 Quarters Earnings $23.4 Million 2/11
Quarterly Earnings Growth 262% 3/11
Annual Earnings Growth -93% 9/11
Quarterly Revenue Growth 146% 2/11
Annual Revenue Growth -39% 11/11
Cash On Hand $179.9 Million 3/11
Short Term Debt $1.2 Million 5/11
Long Term Debt $252.6 Million 1/11

TG Therapeutics, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare TG Therapeutics, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 270.04 1/11
PS 19.19 4/11
PB 28.40 2/11
PC 35.10 5/11
Liabilities to Equity 1.60 3/11
ROA 0.04 3/11
ROE 0.11 5/11
Current Ratio 1.63 7/11
Quick Ratio 0.88 8/11
Long Term Debt to Equity 1.14 3/11
Debt to Equity 1.14 3/11
Burn Rate -13.90 11/11
Cash to Cap 0.03 7/11
CCR -1.10 10/11
EV to EBITDA 196.10 1/11
EV to Revenue 19.42 4/11

Company Details

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.

CEO: Mr. Michael Weiss

Website: https://www.tgtherapeutics.com

Address: 2 Gansevoort St Fl 9 New York City, NEW YORK

Exchange: NASDAQ Capital Market

Industry: Biotechnology

TG Therapeutics, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to TG Therapeutics, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Exelixis, Inc. EXEL $10.3 Billion
Viking Therapeutics, Inc. VKTX $2.9 Billion
Reata Pharmaceuticals, Inc. RETA $6.6 Billion
Intercept Pharmaceuticals, Inc. ICPT $794.7 Million
Madrigal Pharmaceuticals, Inc. MDGL $7.4 Billion
BioXcel Therapeutics, Inc. BTAI $7.6 Million
Hepion Pharmaceuticals, Inc. HEPA $658,800
PDS Biotechnology Corporation PDSB $55.7 Million
X4 Pharmaceuticals, Inc. XFOR $46.2 Million
Terns Pharmaceuticals, Inc. TERN $272.4 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
TGTX Income Statements
Quarter Year Revenue Earnings
Q4 2024 $ 108.2 Million $23.3 Million
Q3 2024 $ 83.9 Million $3.9 Million
Q2 2024 $ 73.5 Million $6.9 Million
Q1 2024 $ 63.5 Million -$10.7 Million
Q4 2023 $ 44.0 Million -$14.4 Million
Q3 2023 $ 165.8 Million $113.9 Million
Q2 2023 $ 16.1 Million -$47.6 Million
Q1 2023 $ 7.8 Million -$38.6 Million

View All

TGTX Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2024 $179.9 Million $577.7 Million $253.7 Million $222.4 Million
Q3 2024 $195.8 Million $586.0 Million $9.7 Million $192.2 Million
Q2 2024 $82.9 Million $401.2 Million $112.5 Million $177.6 Million
Q1 2024 $75.5 Million $373.3 Million $111.7 Million $160.1 Million
Q4 2023 $217.5 Million $329.6 Million $0 $160.5 Million
Q3 2023 $229.2 Million $331.1 Million $11.0 Million -$1.5 Billion
Q2 2023 $97.0 Million -$1.4 Billion $11.3 Million -$1.6 Billion
Q1 2023 $61.5 Million -$1.4 Billion $11.6 Million -$1.6 Billion

View All

TGTX Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q4 2024 -$25.7 Million -$21,000 -$15.9 Million
Q3 2024 -$12.2 Million -$24,000 $114.2 Million
Q2 2024 $5.5 Million $0 $7.4 Million
Q1 2024 -$8.2 Million $0 -$17.5 Million
Q4 2023 $0 $0 $0
Q3 2023 $83.7 Million $0 $53.9 Million
Q2 2023 $0 $0 $0
Q1 2023 -$59.9 Million $0 -$40.8 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions